This “Gallbladder Neoplasms - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Gallbladder Neoplasms pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Gallbladder Neoplasms Understanding
Gallbladder carcinoma is a term referring to primary epithelial malignancies arising from the gallbladder, in which the great majority (90%) are adenocarcinomas and the remainder are squamous cell carcinomas. Symptoms of gallbladder neoplasm include abdominal pain, nausea or vomiting, jaundice, general weakness or fatigue, a lump in the abdomen, weight loss, and fever. The diagnosis of gallbladder neoplasms include blood tests and imaging tests like ultrasound, computerized tomography (CT) and magnetic resonance imaging (MRI). Treatment of gallbladder carcinoma depends on the type and stage of cancer. Management of gallbladder carcinoma is primarily surgical.
"Gallbladder Neoplasms - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gallbladder Neoplasms pipeline landscape is provided which includes the disease overview and Gallbladder Neoplasms treatment guidelines. The assessment part of the report embraces, in depth Gallbladder Neoplasms commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gallbladder Neoplasms collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder Neoplasms R&D. The therapies under development are focused on novel approaches to treat/improve Gallbladder Neoplasms.
This segment of the Gallbladder Neoplasms report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Andes-1537 is a proprietary antisense oligonucleotide designed by Andes Biotechnology. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. The drug is in Phase I clinical studies for the treatment of gall bladder cancer and solid tumor.
Seribantumab is a fully human anti-HER3 (ErbB3) monoclonal antibody, targeting the ErbB3 receptor. Seribantumab demonstrated efficacy in reducing tumor growth in preclinical models of NRG1 fusion-positive gastrointestinal (GI) cancers, suggesting that the use of seribantumab as monotherapy could have clinical utility in treating patients with GI and other NRG1 fusion-driven cancers. The drug is in Phase II clinical studies for the treatment of patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
This segment of the report provides insights about the different Gallbladder Neoplasms drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the therapies for Gallbladder Neoplasms. The companies which have their Gallbladder Neoplasms drug candidates in the most advanced stage, i.e. Phase II include, Elevation Oncology.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Gallbladder Neoplasms therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gallbladder Neoplasms drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Gallbladder Neoplasms Understanding
Gallbladder Neoplasms: Overview
Gallbladder carcinoma is a term referring to primary epithelial malignancies arising from the gallbladder, in which the great majority (90%) are adenocarcinomas and the remainder are squamous cell carcinomas. Symptoms of gallbladder neoplasm include abdominal pain, nausea or vomiting, jaundice, general weakness or fatigue, a lump in the abdomen, weight loss, and fever. The diagnosis of gallbladder neoplasms include blood tests and imaging tests like ultrasound, computerized tomography (CT) and magnetic resonance imaging (MRI). Treatment of gallbladder carcinoma depends on the type and stage of cancer. Management of gallbladder carcinoma is primarily surgical.
"Gallbladder Neoplasms - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gallbladder Neoplasms pipeline landscape is provided which includes the disease overview and Gallbladder Neoplasms treatment guidelines. The assessment part of the report embraces, in depth Gallbladder Neoplasms commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gallbladder Neoplasms collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder Neoplasms R&D. The therapies under development are focused on novel approaches to treat/improve Gallbladder Neoplasms.
Gallbladder Neoplasms Emerging Drugs Chapters
This segment of the Gallbladder Neoplasms report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gallbladder Neoplasms Emerging Drugs
Andes-1537: Andes Biotechnologies
Andes-1537 is a proprietary antisense oligonucleotide designed by Andes Biotechnology. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. The drug is in Phase I clinical studies for the treatment of gall bladder cancer and solid tumor.
Seribantumab: Elevation Oncology
Seribantumab is a fully human anti-HER3 (ErbB3) monoclonal antibody, targeting the ErbB3 receptor. Seribantumab demonstrated efficacy in reducing tumor growth in preclinical models of NRG1 fusion-positive gastrointestinal (GI) cancers, suggesting that the use of seribantumab as monotherapy could have clinical utility in treating patients with GI and other NRG1 fusion-driven cancers. The drug is in Phase II clinical studies for the treatment of patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
Gallbladder Neoplasms: Therapeutic Assessment
This segment of the report provides insights about the different Gallbladder Neoplasms drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Gallbladder Neoplasms
There are approx. 10+ key companies which are developing the therapies for Gallbladder Neoplasms. The companies which have their Gallbladder Neoplasms drug candidates in the most advanced stage, i.e. Phase II include, Elevation Oncology.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Gallbladder Neoplasms pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Gallbladder Neoplasms: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Gallbladder Neoplasms therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gallbladder Neoplasms drugs.
Gallbladder Neoplasms Report Insights
- Gallbladder Neoplasms Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Gallbladder Neoplasms Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gallbladder Neoplasms drugs?
- How many Gallbladder Neoplasms drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gallbladder Neoplasms?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gallbladder Neoplasms therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gallbladder Neoplasms and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Andes Biotechnologies
- Merck
- Elevation Oncology
- Leap Therapeutics
- Ipsen
- Ohara Pharmaceuticals
- AstraZeneca
- Elicio Therapeutics
- Array BioPharma
Key Products
- Andes-1537
- M7824
- Seribantumab
- DKN 01
- Irinotecan sucrosofate
- ONC 201
- Tremelimumab
- ELI 002
- Tucatinib
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Gallbladder Neoplasms: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Gallbladder Neoplasms - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Seribantumab: Elevation Oncology
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Andes-1537: Andes Biotechnologies
- Product Description
- Research and Development
- Product Development Activities
Preclinical/Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Gallbladder Neoplasms Key Companies
Gallbladder Neoplasms Key Products
Gallbladder Neoplasms- Unmet Needs
Gallbladder Neoplasms- Market Drivers and Barriers
Gallbladder Neoplasms- Future Perspectives and Conclusion
Gallbladder Neoplasms Analyst Views
AppendixList of Tables
Table 1 Total Products for Gallbladder Neoplasms
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Gallbladder Neoplasms
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Andes Biotechnologies
- Merck
- Elevation Oncology
- Leap Therapeutics
- Ipsen
- Ohara Pharmaceuticals
- AstraZeneca
- Elicio Therapeutics
- Array BioPharma